Floatz logo

Blinatumomab

IKZF1 Gene Mutation

Nanfang Hospital, Southern Medical Universitymonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

3 Active assets in the IKZF1 Gene Mutation cohort.

Asset / SponsorPhaseRating
Olverembatinib
Nanfang Hospital, Southern Medical University
Phase 2CCC
Tucidinostat
Nanfang Hospital, Southern Medical University
Phase 2CCC
PREDNISONE TABLETS
Nanfang Hospital, Southern Medical University
Phase 2CCC

Same molecule, other indications

Blinatumomab is also rated in:

precursor B-cell acute lymphoblastic leukemiaDormant
BBB
Indicative ·
72 / 100
View asset →
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
BBB
Indicative ·
72 / 100
View asset →
Precursor B-Cell Acute Lymphoblastic LeukemiaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →